Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746932 | 1.00 | HTT (0.48) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL19522401 | 1.00 | HTT (0.48) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL21259228 | 1.00 | HTT (0.48) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL19334136 | 1.00 | HTT (0.48) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL18816226 | 0.98 | HTT (0.47) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL5522050 | 0.97 | HTT (0.46) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL23879489 | 0.94 | ALDH1A1 (0.49) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL10290163 | 0.94 | ALDH1A1 (0.49) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL21538501 | 0.90 | HTT (0.47) | HTTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL22264520 | 0.87 | ALDH1A1 (0.54) | HTTSMN1; SMN2POLBLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | HTT 4383/4885MEN1 3463/4885KMT2A 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.